SOURCE: The Bedford Report

The Bedford Report

July 07, 2011 08:16 ET

MannKind and Amylin Embrace the Future of Diabetes Treatment

The Bedford Report Provides Equity Research on MannKind and Amylin Pharmaceuticals

NEW YORK, NY--(Marketwire - Jul 7, 2011) - In the United States alone, more than 21 million people suffer from diabetes, and the number is growing at a rate of 10 percent annually. This rapid growth has provided significant opportunities for pharmaceutical companies who are able to develop new therapies to address type 1 and 2 diabetes. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides equity research on MannKind Corporation (NASDAQ: MNKD) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). Access to the full company reports can be found at:

According to Frost & Sullivan research titled "US Diabetes Drug Delivery -- Patient Perspective," the future of diabetes treatments is in the convenient drug delivery methods. Type-1 diabetic patients are most likely to prefer a twice-a-day oral dosing regimen, while type-2 diabetic patients are also expected to prefer a twice-a-day oral dosing regimen or a twice-a-day patch.

MannKind's leading drug candidate, AFREZZA®, is an ultra-rapid acting inhalable insulin that (if approved) will allow diabetes patients to inhale AFREZZA before a meal. MannKind is trying to show the FDA that the drug does not cause dangerous side effects to a patient's heart.

The Bedford Report releases investment research on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Amylin Pharmaceuticals is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces two drugs, Symlin and Byetta. Amylin says that Symlin "is the first and only analogue of the human hormone amylin -- a partner to insulin -- and a first-in-class diabetes therapy offering improved glucose control with potential for weight loss."

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information